A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
The study will investigate the effects and the safety of a single-dose of ABX-1431 HCl on
tics and other symptoms of Tourette Syndrome.
During part 1 (periods 1 and 2) each patient will receive study drug once and placebo once.
Patients who complete part 1 with adequate clinical safety will be offered the option to
participate in part 2 (periods 3 and 4) and again willl receive study drug once and placebo
once where, in contrast to part 1, administration will take place with a standard high fat
meal.